Cargando…

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket

The deep hydrophobic pocket of HIV-1 gp41 has been considered a drug target, but short-peptides targeting this site usually lack potent antiviral activity. By applying the M-T hook structure, we previously generated highly potent short-peptide fusion inhibitors that specifically targeted the pocket...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiujuan, Zhu, Yuanmei, Hu, Hao, Zhang, Senyan, Wang, Pengfei, Chong, Huihui, He, Jinsheng, Wang, Xinquan, He, Yuxian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834435/ https://www.ncbi.nlm.nih.gov/pubmed/29535974 http://dx.doi.org/10.3389/fcimb.2018.00051

Ejemplares similares

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41
por: Yan, Hongxia, et al.
Publicado: (2022)

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors
por: Geng, Xiuzhu, et al.
Publicado: (2019)

Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy
por: Chen, Yue, et al.
Publicado: (2021)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity
por: Zhu, Yuanmei, et al.
Publicado: (2020)

Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
por: Yu, Fei, et al.
Publicado: (2013)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021)

SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses
por: Zhu, Yuanmei, et al.
Publicado: (2021)

Targeting a Conserved Lysine in the Hydrophobic Pocket of HIV-1 gp41 Improves Small Molecule Antiviral Activity
por: He, Li, et al.
Publicado: (2022)

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
por: Yu, Danwei, et al.
Publicado: (2020)

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques
por: Chong, Huihui, et al.
Publicado: (2019)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions
por: Qi, Qianqian, et al.
Publicado: (2017)

Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope
por: Penn-Nicholson, Adam, et al.
Publicado: (2008)

Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41
por: Muñoz-Barroso, Isabel, et al.
Publicado: (1998)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding
por: Kahle, Kristen M., et al.
Publicado: (2009)

Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor
por: Sun, Youxiang, et al.
Publicado: (2017)

Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor
por: Chong, Huihui, et al.
Publicado: (2012)

Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions
por: Buzon, Victor, et al.
Publicado: (2010)

Identification of a Human Protein-Derived HIV-1 Fusion Inhibitor Targeting the gp41 Fusion Core Structure
por: Chao, Lijun, et al.
Publicado: (2013)

gp41: HIV's shy protein
por: Zwick, Michael B, et al.
Publicado: (2004)

Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics
por: De Feo, Christopher J, et al.
Publicado: (2014)

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor
por: Hu, Yue, et al.
Publicado: (2022)

Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif
por: Wu, Tong, et al.
Publicado: (2022)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
por: Yu, Danwei, et al.
Publicado: (2021)

Mutational analysis of HIV-1 gp41 mediated apoptosis and its correlation with fusion/hemifusion
por: Garg, Himanshu, et al.
Publicado: (2006)

Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay
por: Sardari, Soroush, et al.
Publicado: (2013)

HIV gp41-Mediated Membrane Fusion Occurs at Edges of Cholesterol-Rich Lipid Domains
por: Yang, Sung-Tae, et al.
Publicado: (2015)

Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1
por: Pu, Jing, et al.
Publicado: (2021)

Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41
por: Dennison, S. Moses, et al.
Publicado: (2011)

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides
por: Hu, Yue, et al.
Publicado: (2023)

Characterization of Gp41 Polymorphisms in the Fusion Peptide Domain and T-20 (Enfuvirtide) Resistance-Associated Regions in Korean HIV-1 Isolates
por: Jang, Dai-Ho, et al.
Publicado: (2014)

Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein
por: Joshi, Vinita R., et al.
Publicado: (2020)

Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action
por: Wang, Chen, et al.
Publicado: (2019)

Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy
por: Jin, Hongliang, et al.
Publicado: (2021)

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein
por: Vassell, Russell, et al.
Publicado: (2015)

Folded Monomers and Hexamers of the Ectodomain of the HIV gp41 Membrane Fusion Protein: Potential Roles in Fusion and Synergy Between the Fusion Peptide, Hairpin, and Membrane-Proximal External Region
por: Banerjee, Koyeli, et al.
Publicado: (2014)

Antibodies and vaccines against Middle East respiratory syndrome coronavirus
por: Xu, Jiuyang, et al.
Publicado: (2019)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vfr6pdld6s478kjr56t4dhe3i2